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Abstract
Introduction: Total 25-hydroxyvitamin D [25(OH)D] is the most reliable indicator of vitamin D status. In this study, we compared two automated 
immunoassay methods, the Abbott Architect 25-OH Vitamin D assay and the Roche Cobas Vitamin D total assay, with the liquid chromatography-
tandem mass spectrometry (LC-MS/MS).
Materials and methods: One hundred venous blood samples were randomly selected from routine vitamin D tests. Two of the serum aliquots 
were analyzed at the Abbott Architect i2000 and the Roche Cobas 6000’s module e601 in our laboratory within the same day. The other serum 
aliquots were analyzed at the LC-MS/MS in different laboratory. Passing-Bablok regression analysis and Bland-Altman plot were used to compare 
methods. Inter-rater agreement was analyzed using kappa (κ) analysis. 
Results: The Roche assay showed acceptable agreement with the LC-MS/MS based on Passing-Bablok analysis (intercept: -5.23 nmol/L, 95% CI: 
-8.73 to 0.19; slope: 0.97, 95% CI: 0.77 to 1.15). The Abbott assay showed proportional (slope: 0.77, 95% CI: 0.67 to 0.85) and constant differences 
(intercept: 17.08 nmol/L; 95% CI: 12.98 to 21.39). A mean bias of 15.1% was observed for the Abbott and a mean bias of -14.1% was observed for the 
Roche based on the Bland-Altman plots. We found strong to nearly perfect agreement in vitamin D status between the immunoassays and LC-MS/
MS. (κ: 0.83 for Abbott, κ: 0.93 for Roche) using kappa analysis.
Conclusion: Both immunoassays demonstrated acceptable performance, but the Roche Cobas assay demonstrated better performance than the 
Abbott Architect in the studied samples.
Key words: 25-Hydroxyvitamin D; chromatography; immunoassay; methods; tandem mass spectrometry
Received: January 04, 2015 Accepted: August 28, 2015
A comparison between two different automated total 25-hydroxyvitamin 
D immunoassay methods using liquid chromatography-tandem mass 
spectrometry 
Fatma Emel Kocak*1, Bahadir Ozturk2, Ozben Ozden Isiklar3, Ozlem Genc4, Ali Unlu2, Irfan Altuntas1
1Dumlupinar University, Faculty of Medicine, Department of Medical Biochemistry, Kutahya, Turkey
2Selcuk University, Faculty of Medicine, Department of Medical Biochemistry, Konya, Turkey
3Dumlupinar University, Evliya Celebi Education and Research Hospital, Department of Medical Biochemistry, Kutahya, Turkey




Vitamin D, also known as the “sunshine vitamin,” is 
a lipid-soluble nutrient that is obtained from die-
tary sources as ergocalciferol (D2) or cholecalcifer-
ol (D3) (1). Although vitamin D is classically known 
for its role in bone metabolism, it plays an impor-
tant role in the body beyond its functions in the 
musculoskeletal system (2). Previous studies have 
reported that vitamin D is not only required for 
bone health, but also plays a role in autoimmune 
diseases, obesity, type 2 diabetes mellitus, meta-
bolic syndrome, cardiovascular diseases, and cer-
tain types of cancer. These reports have led to an 
increase in requests for vitamin D tests by clini-
cians in recent years (3-5).
25-Hydroxyvitamin D [25(OH)D] (calcidiol) has a 
half-life of several weeks; therefore, the most accu-
rate method of determining vitamin D status is to 
measure 25(OH)D. Serum 25(OH)D concentration 
represents endogenous vitamin D synthesis in the 
skin as well as dietary intake. Measurement of 
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1,25-dihydroxyvitamin D [1,25(OH)2D] (calcitriol) is 
not a good indicator of the vitamin D status, as it 
has a very short half-life of approximately 4 h, and 
its blood levels are closely regulated by the serum 
levels of parathyroid hormone, calcium, and phos-
phate. Calcitriol concentration also does not re-
flect the vitamin D reserves, as levels are frequent-
ly elevated in individuals with hypovitaminosis D 
because of secondary hyperparathyroidism. 
Therefore, total 25(OH)D is the most reliable indi-
cator of vitamin D status (6,7).
Although the use of vitamin D testing has recently 
increased substantially, there is little consensus on 
which assay should be used to measure its con-
centration, and there are serious concerns regard-
ing the reliability of its measurement (7). To cor-
rectly assess vitamin D status, a method for relia-
bly measuring 25(OH)D is needed. Several specifi-
cations should be considered when selecting a vi-
tamin D assay, including total 25(OH)D measure-
ment (the sum of 25(OH)D2 and 25(OH)D3), accura-
cy, reproducibility, turn-around time, inter-assay 
comparability, and cost- effectiveness (8). Until re-
cently, no generally accepted reference method 
for 25(OH)D measurement was available. In 2010, 
Tai et al. developed isotope dilution liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) 
as a candidate reference method, which in 2011 
was recognized as a reference method by the Joint 
Committee for Traceability in Laboratory Medicine 
(9). Isotope dilution LC-MS/MS is currently consid-
ered the reference method for 25(OH)D measure-
ment, as it can simultaneously quantitate 25(OH)
D2 and 25(OH)D3; these values are summed to de-
termine total 25(OH)D (10). Recently, some manu-
facturers have developed automated immunoas-
says for 25(OH)D measurement, including Sie-
mens, IDS, Abbott, Roche, and DiaSorin. Except for 
the Roche assay, all current automated tests use a 
similar method design. Sample pretreatment dis-
sociates 25(OH)D from vitamin D binding protein 
(VDBP), and 25(OH)D competes with exogenous 
labeled 25(OH)D for binding to assay specific anti-
bodies. The Roche assay is a competitive protein-
binding assay and uses exogenous recombinant 
human VDBP to capture 25(OH)D in the patient 
sample (11).
Because 25(OH)D is highly lipophilic and has 
strong binding affinity for VDBP, it is not easy or 
simple to measure its concentration in patient 
sera. There is a great deal of variety among 25(OH)
D assays because of the different techniques em-
ployed for separating 25(OH)D from its binding 
protein, as well as its detection and measurement 
(12). Although LC-MS/MS is considered the refer-
ence method for measuring 25(OH)D concentra-
tions, the instrument is very expensive, unavaila-
ble in most clinical laboratories, and its turnaround 
time is relatively longer than that of immunoas-
says. Therefore, automated and high-throughput 
immunoassays may be a good alternative for clini-
cal laboratories. However, there is no strong agree-
ment between the current immunoassay methods 
because of intermethod variability due to the dif-
ferent standardizations used (12,13). In coopera-
tion with the National Institutes of Health’s Office 
of Dietary Supplements, the National Institute of 
Standards and Technology (NIST) developed 
standard reference materials (SRMs) in order to im-
prove accuracy and to enable worldwide stand-
ardization for 25(OH)D measurement. The SRM 
2972 contains defined amounts of 25(OH)D2 and 
25(OH)D3 dissolved in ethanol. This material is 
used for direct calibration of LC-MS/MS reference 
measurement procedures. While this material can 
be used with chromatographic methods as cali-
brators, the antigen-antibody reaction prevents 
direct calibration of immunological methods by 
using this calibration solution. Therefore, serum-
based materials are needed for calibration of im-
munological methods. The NIST developed se-
rum-based reference material, SRM 972, which 
consists of four pools of human serum with ana-
lyte values for 25(OH)D2, 25(OH)D3, and 3-epi-
25(OH)D3. Despite these standardization efforts, 
unresolved discrepancies and unacceptable biases 
persist between immunoassays compared to the 
reference methods. Therefore, further standardi-
zation studies for 25(OH)D measurements should 
be conducted to obtain reliable results and to cor-
rectly define the vitamin D status in patients (14).
Vitamin D testing orders have increased by 20-fold 
in the past 3 years in our laboratory, with nearly 
75% of results indicating vitamin D deficiency or 
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insufficiency. Therefore, in this study we compared 
two automated immunoassay methods, the Ab-
bott Architect 25-OH Vitamin D assay and the 
Roche Cobas Vitamin D total assay, while referenc-
ing the LC-MS/MS method to verify our routine 
25(OH)D measurements. In this study, methods 
were compared by considering recommendations 
of the Clinical and Laboratory Standards Institute 
(CLSI) Evaluation Protocol 9 (EP09-A3) specifica-
tions (15). This document provides guidance for 
designing an experiment and selecting methods 
for quantifying systematic measurement error 
(bias or difference) between measurement proce-
dures based on comparison of patient samples. 
Given the the increase in use of vitamin D testing 
day by day, findings of this study would provide 
substantial data about comparability of common-
ly used two immunoassay methods with LC-MS/
MS method for laboratory professionals.  
Materıals and methods
Study design
This method comparison study was carried out at 
the Evliya Celebi Research and Education Hospital 
of Dumlupinar University and the Medical Faculty 
Hospital of Selcuk University, Turkey in November 
2014. The study was carried out in accordance with 
the Declaration of Helsinki. One hundred venous 
blood samples from 70 adult females and 30 adult 
males were randomly selected from our routine vi-
tamin D test requests. The total number of daily 
25(OH)D test requests is 110-120 in our hospital.
Collection of samples and measurement of 
serum total 25(OH)D
After an overnight fasting, venous blood samples 
were collected into an evacuated serum separator 
clot activator tube (Vacuette® Z Serum Sep Clot 
Activator, GreinerBio-One, Kremsmunster, Austria) 
between 9 a.m. and 10 a.m. Blood samples were 
centrifuged at 1500 × g for 10 min within 1 h of 
collection. Hemolytic, lipemic, and icteric serum 
samples and samples collected in inadequate test 
tubes or samples with insufficient volume were 
excluded from the study. The serum samples were 
aliquoted into three separate polystyrene tubes. 
Two aliquots were immediately processed on the 
following platforms: Abbott Architect i2000 (Ab-
bott Laboratories, Wiesbaden, Germany) by 
chemiluminescent microparticle immunoassay us-
ing Abbott Architect 25-OH Vitamin D assay rea-
gent (Abbott Laboratories, Wiesbaden, Germany) 
and Roche Cobas 6000’s module e601 (Roche Di-
agnostics GmbH, Mannheim, Germany) by electro-
chemiluminescence immunoassay using Roche 
Cobas Vitamin D total assay reagent (Roche Diag-
nostics GmbH, Mannheim, Germany). Samples 
were processed in a single batch in duplicate on 
each analyzer according to the manufacturer’s in-
structions. Calibration curves were constructed us-
ing calibrators provided in the kits. The third ali-
quot was stored at -20 °C. After 1 week of storage, 
collected aliquots were transported to the Medical 
Faculty Hospital of Selcuk University on dry ice for 
25(OH)D analysis by LC-MS/MS. Before analysis, 
frozen samples were thawed and single process-
ing was conducted. The LC-MS/MS assay method 
was adapted from a method described by Sahillio-
glu et al. (16). MS detection was carried out with an 
AB Sciex API 3200 triple quadrupole liquid tandem 
mass spectrometer (AB Sciex Instruments, Biopo-
lis, Singapore) using atmospheric pressure chemi-
cal ionisation as the ionization source. Multiple re-
action monitoring positive ion mode was used to 
detect 25-hydroxy metabolites of vitamin D and 
deuterium-labeled internal standard [2H6-25(OH)
D3] (DLM-9116, Cambridge Isotope Laboratories, 
Inc., Andover, MA, USA). Chromatographic separa-
tion of 25(OH)D3 was carried out using a chroma-
tography unit (Shimadzu Prominence SIL LC-20, 
Shimadzu Corporation, Kyoto, Japan) and a C18 re-
verse phase column (Phenomenex, Luna Analyti-
cal Column, Torrance, CA, USA). The samples were 
prepared using a protein precipitation protocol 
and the analyte was extracted by protein crash 
with acetonitrile. Quantitation was performed by 
linear regression of peak area ratios of 25(OH)D3 / 
2H6-25(OH)D3 against the calibrator concentra-
tions (IC3402ka CAL, ImmuChrom GmbH, Heppen-
heim, Germany). Measurement ranges of the as-
says were 20.0-400.0 nmol/L for the Abbott Archi-
tect 25-OH Vitamin D assay, 7.5–175.0 nmol/L for 
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the Roche Cobas Vitamin D total assay, and 10.0-
2500.0 nmol/L for the LC-MS/MS assay. Internal 
quality control samples were included in the assay 
run and intra-assay coefficients of variation (CVs) 
values were obtained from the measurements. For 
Architect i2000 analysis, intra-assay CVs were 4.2%, 
2.7%, and 2.2%, with target values of 47.5 nmol/L, 
95.0 nmol/L, and 195.0 nmol/L (Architect 25-OH 
Vitamin D Control L, M, and H, Abbott Laborato-
ries, Wiesbaden, Germany). For Cobas e601analy-
sis, intra-assay CVs were 4.9% and 3.1%, with target 
values of 50.5 nmol/L, and 99.0 nmol/L (PreciCon-
trol Varia 1 and 2, Roche Diagnostics GmbH, Man-
nheim, Germany). For LC-MS/MS analysis, intra-as-
say CVs were 3.8% and 2.3%, with target values of 
57.1 nmol/L and 127.0 nmol/L (IC3402ko CTRL 1 
and 2, ImmuChrom GmbH, Heppenheim, Germa-
ny).
Statistical analysis
The 25(OH)D results obtained by LC-MS/MS were 
used as the reference for method comparison 
studies. Results reading below or above the lower 
or upper limit of measurement ranges of the im-
munoassay methods were omitted from statistical 
evaluation. Concentrations of 25(OH)D were given 
in nmol/L International System of Units (SI). All 
data sets were tested for normality using Kolmog-
orov-Smirnov test. Passing-Bablok regression anal-
ysis was used to assess constant and proportional 
biases between methods, including the Cusum 
test for linearity. A P value < 0.05 indicates a signif-
icant deviation from linearity. For significant agree-
ment, the 95% confidence interval (CI) of the inter-
cept should contain the zero, while the 95%CI of 
the slope should contain 1 (17). A Bland-Altman 
plot was used to assess differences and biases be-
tween methods. Bland and Altman recommend 
plotting differences against the average of the 
methods rather than against that of the reference 
method, while CLSI recommends plotting differ-
ences against the reference method (15,18). There-
fore, differences between values from compara-
tive immunoassays and the reference method 
against the reference method value were dis-
played in the difference plots according to CLSI 
recommendations. The differences expressed as a 
percentage of the reference method value were 
plotted to illustrate whether the difference be-
tween the measurements made using the two 
methods was related to the magnitude of the 
measurement. Inter-rater agreement in assess-
ment of vitamin D status between assays was ana-
lyzed using kappa (κ) analysis (19). A kappa value 
of 1.0 indicates perfect agreement, >0.90 indicates 
almost perfect agreement; 0.80-0.90 indicates 
strong agreement, 0.60-0.79 indicates moderate 
agreement, 0.40-0.59 indicates weak agreement, 
0.21-0.39 indicates minimal agreement, and <0.20 
indicates no agreement between methods. Statis-
tical analysis was performed using MedCalc soft-
ware (version 9.2.0.1, MedCalc Software, Ostend, 
Belgium).
Results
25(OH)D results obtained by LC-MS/MS were used 
as the reference and the range of the samples was 
11.0 to 427.5 nmol/L as measured by LCMS/MS. Val-
ues <20.0 nmol/L were excluded from statistical 
analyses using the Architect method, as its lower 
measurement range is 20.0 nmol/L according to 
the manufacturer. Values > 175.0 nmol/L were ex-
cluded from statistical analyses with the Cobas 
method, as its upper measurement range is 175.0 
nmol/L according to the manufacturer. Overall, 83 
complete cases of the 100 examined could be 
evaluated for Architect and, 79 complete cases 
could be evaluated for Cobas statistical analysis. 
25(OH)D2 concentrations were undetectable in LC/
MS-MS measurements. Thus, all comparison data 
were obtained from Architect i2000, Cobas e601, 
and LC-MS/MS represented 25(OH)D3 solely. We 
found that all data from the three different assay 
methods were not distributed normally based on 
Kolmogorov-Smirnov tests (P < 0.001). The exam-
ined ranges of the 25(OH)D concentrations (mini-
mum to maximum) were 9.1-352.5 nmol/L as 
measured by LCMS/MS, 7.5-129.0 nmol/L as meas-
ured by Cobas e601, 26.5- 96.5 nmol/L as meas-
ured by Architect i2000. 
The slope and intercept of the Passing-Bablok re-
gression line for each immunoassay method were 
compared with those of the LC-MS/MS assay meth-
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od. Details regarding the Passing-Bablok regres-
sion analysis are shown in Table 1. 
Differences and biases between methods were 
evaluated using a Bland-Altman plot (Figure 1 and 
2). 
25(OH)D results were classified to define vitamin D 
status, as recommended by The Endocrine Socie-
ty’s Clinical Practice Guideline on Vitamin D (20). 
We compared the proportion of samples fulfilling 
vitamin D deficiency using the 50 nmol/L cut-off 
by different assays using κ analysis (Table 2). 
Statistical analysis
LC-MS/MS (variable x)
Architect i2000 (variable y)
(nmol/L)
LC-MS/MS (variable x)
Cobas e601 (variable y)
(nmol/L)
N 83 79
Regression equation y=17.08 (12.98-21.39) + 0.77 (0.67-0.85) x y=-5.23 (-8.73-0.19) + 0.97 (0.77-1.15) x
Random differences
RSD






Cusum test for linearity P = 0.40 P = 0.90
RSD - residual standard deviation, CI - confidence interval. 
Table 1. Details regarding the Passing-Bablok regression analysis.
Figure 2. Comparison of the Roche Cobas e601 Vitamin D to-
tal immunoassay method with LC-MS/MS method using Bland-
Altman analysis.
Figure 1. Comparison of the Abbott Architect i2000 25-OH Vi-
tamin D immunoassay method with LC-MS/MS method using 
Bland-Altman analysis.
Dıscussıon
Our results revealed that both immunoassays 
demonstrated acceptable performance. The re-
sults of both methods were comparable to those 
of LC–MS/MS based on Passing Bablok regression 
analysis. A mean bias of 15.1% was observed for 
the Abbott Architect and a mean bias of -14.1% 
was observed for the Roche assay based on the 
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lead to overestimation or underestimation of 
25(OH)D concentrations. In addition, both meth-
ods had some limitations when their performance 
was challenged with samples containing low and 
high total 25(OH)D concentrations. We found 
higher concentration-dependent deviation for us-
ing Abbott Architect measurements compared to 
that using LC-MS/MS. The Roche assay showed 
better performance than the Abbott assay. 
Consistent with the findings of this study, Farrell et 
al. found a mean bias of 40.9% between the Ab-
bott Architect and LC-MS/MS methods for whole 
study samples (N = 170) with concentrations rang-
ing from 5.0 to 151.0 nmol/L and a mean bias of 
104.5% for samples with concentrations <20.0 
nmol/L as assessed by LC-MS/MS (22). They sug-
gest that this excessive positive bias does not pre-
sent a serious problem when the assay is used ac-
cording to the manufacturer’s specification, which 
recommends not reporting results <20.0 nmol/L 
(21). In our study, although the samples with con-
centrations <20.0 nmol/L were excluded from 
analysis, a mean bias of 15.1% was found. Holmes 
et al. found that the Abbott Architect assay had a 
bias of 40% at 25(OH)D3 concentrations <50.0 
nmol/L (N = 94), and they suggest that this posi-
tive bias for samples at the lower end of the ana-
lytical measuring range is likely due to a standardi-
zation or calibration defect or a common, positive 
interfering substance that was not measured by 
LC-MS/MS (22). Ong et al. also found significant 
positive bias for the Abbott Architect assay com-
pared to LC-MS/MS (N = 200) (23). Clinically, 25(OH)
D concentrations <50.0 nmol/L indicate vitamin D 
deficiency; thus, inaccuracies at low concentra-
tions have a limited impact on treatment deci-
sions. In this study, the Roche Cobas Vitamin D to-
tal assay method showed a bias of -14.1%. Previous 
studies evaluating the Cobas methods found neg-
ative bias compared to that of LC-MS/MS, which 
was similar to the results of our study (24,25).
There are several explanations for the observed 
inter-method differences between the immunoas-
says and LC-MS/MS. First, the differences between 
the immunoassays and LC-MS/MS method may 
have resulted from different calibrator traceability. 
The Roche Cobas Vitamin D total assay has been 
standardized against LC-MS/MS which in turn has 
been standardized to the NIST standard. The Ab-
bott Architect 25-OH Vitamin D assay is traceable 












Architect i2000 0 37 (44%) 14 (17%) 32 (39%)
LC-MS/MS 15 (18%) 29 (35%) 5 (6%) 34 (41%)
N = 79
Cobas e601 40 (50%) 23 (29%) 6 (8%) 10 (13%)
LC-MS/MS 32 (40%) 29 (37%) 5 (7%) 13 (16%)
LC–MS/MS N = 83
Architect i2000









37                  7
                    39
0.83 (0.71-0.95)
61              
2                16
0.93 (0.82-1.03)
CI - confidence interval, κ - Kappa.
25(OH)D results were classified to define vitamin D status, as recommended by The Endocrine Society’s Clinical Practice Guideline 
on Vitamin D (20).
Table 2. Classification of vitamin D status and inter-rater agreement between LC-MS/MS and two immunoassay methods according 
to 25(OH)D based on 50.0 nmol/L cut-off. 
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to the manufacturer’s internal standard (primary 
calibrator) against an absorbance of 264 nm. This 
may explain the better agreement between the 
Roche method and LC-MS/MS compared to the 
Abbott method. Additionally, cross-reactivity may 
have occurred with other metabolites of 25(OH)D. 
All immunoassays for 25(OH)D show high cross-re-
activity with 24,25(OH)2D, which may be present in 
the serum at concentrations of up to about 10-15 
nmol/L (12). The presence of the 24,25(OH)2D can 
lead to increased 25(OH)D concentrations meas-
ured by immunoassays. The Abbott assay manu-
facturer states that 112% cross-reactivity occurs 
with 24,25(OH)2D3, while Roche assay manufactur-
er claims to have 149% cross-reactivity with 
24,25(OH)2D3. In addition, differential cross-reac-
tivity of 25(OH)D2 in immunoassays is another po-
tential problem; however, this was not an issue for 
the differences observed between the assays in 
our study because 25(OH)D2 concentrations were 
undetectable in the studied samples. This situa-
tion may be explained by vitamin D3 supplemen-
tation which is common in our region.
Matrix effects are known to occur in immunoas-
says and can lead to false high or low results. The 
most important type of matrix effect is any effect 
that occurs between the matrix in the calibrants 
and the patient samples (13). Abbott assay’s cali-
brators are composed of phosphate-buffered sa-
line containing heat-inactivated horse serum and 
Roche assay’s calibrators contain human serum as 
a matrix. Another factor may be the ability of an 
assay to separate 25(OH)D from its binding pro-
tein. In LC/MS-MS methods, 25(OH)D is separated 
from its binding protein by solvent extraction. 
However, in immunoassay methods, solvent ex-
traction and chromatographic separation have 
been replaced by various blocking agents that dis-
place 25(OHD) from VDBP, which shows varying 
success. Although this simplified sample pre-treat-
ment method enables the use of high sample-
throughput and automation, in case of incomplete 
extraction, false low 25(OH)D concentrations may 
be obtained. Strong binding between the highly 
hydrophobic 25(OH)D and VDBP creates competi-
tion with the capturing antibodies. VDBP must be 
be inactivated or completely removed from the 
sample, as residual active VDBP at concentrations 
as low 4 nmol/L (0.5% of total VDBP) may interfere 
with the assay (10,11,26). A recent study, including 
50 healthy individuals, 52 pregnant women, 50 he-
modialysis patients, and 50 intensive care patients 
suggested that in automated assays, not all of the 
25(OH)D was extracted from the VDBP (27). The 
authors observed an inverse relationship between 
VDBP concentrations and deviations of immuno-
assay results from LC-MS/MS results. The Abbott 
assay (Architect i2000) showed VDBP concentra-
tion-dependent differences, but the Roche assay 
(Modular Analytics E170) did not show these differ-
ences (27). The Abbott assay uses 8-anilino-1 naph-
thalenesulfonic acid in triethanolamine methanol 
buffer to separate 25(OH)D from VDBP. In the 
Roche assay, pre-treatment of the sample involves 
an acidic pH change (with dithiothreitol) which in-
activates the DBP and separates the bound 25(OH)
D.
The Endocrine Society’s Clinical Practice Guideline 
on Vitamin D suggests that 25(OH)D levels below 
50.0 nmol/L are deficient, 51.0-75.0 nmol/L are in-
sufficient, and 75.0-250.0 nmol/L are sufficient (20). 
After classification of the 25(OH)D results accord-
ing to recommendations of The Endocrine Society, 
we analyzed inter-rater agreement using the κ sta-
tistic and found strong to nearly perfect agree-
ment in vitamin D status between the immunoas-
says and LC-MS/MS. These results are consistent 
with the findings of previous studies (22,28). 
This study had some limitations. According to CLSI 
EP09-A3 specifications, analysis by comparative 
and test methods should be performed within a 
time span consistent with analyte stability. For all 
analytes, the time span until analysis should not 
exceed 2 h for analysis for each method and, if 
possible, samples should be drawn on the day of 
analysis. In this study, because the 25(OH)D meas-
urements by LC-MS/MS were performed in a dif-
ferent hospital, measurements by immunoassay 
and LC-MS/MS were performed within different 
time spans. Additionally, we did not investigate 
the influence of C3-epi-25(OH)D. The LC-MS/MS 
method used in this study could not separate the 
different epimer forms of vitamin D, particularly 
3-epi-25(OH)D3 and 3-epi-25(OH)D2. If these 
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epimers are available in samples, assay methods 
using 25(OH)D measurements may detect epimers 
within total 25(OH)D concentrations without sepa-
ration, leading to biases due to cross-reactions. A 
recent study by Farrell et al. detected C3-epi-
25(OH)D3 in 40.4% of healthy adults; the authors 
suggested that the C3-epimer of 25(OH)D was a 
source of analytical variance in immunoassays (29). 
Another limitation may be the difference in treat-
ment between the samples used in the immuno-
assays (fresh) and the LC-MS/MS (one freeze/thaw 
cycle), but a recent study reported that long-term 
frozen storage does not affect serum vitamin D 
levels and that 25(OH)D is stable for 7 days at -20 
°C (30). Additionally, sample collection tube used 
in this study may be possible preanalytical source 
of differences on different assays. However, in a 
previous study, the difference between serum 
separator tube with clot activator and EDTA tube 
was investigated and there was no difference be-
tween serum and plasma vitamin D concentration; 
the authors suggested that the choice of collec-
tion tube was not to affect vitamin D concentra-
tion (30).
Conclusıon
In this study, we found that both immunoassays 
demonstrated acceptable performance, but had 
some limitations when their performance was 
challenged with samples containing low and high 
total 25(OH)D concentrations. We found that the 
deviation increased in a concentration-dependent 
manner using Abbott Architect measurements 
compared to using LC-MS/MS. The Roche Cobas 
assay demonstrated better performance than the 
Abbott Architect in the studied samples. There-
fore, immunoassay methods can give variable re-
sults, which is most apparent when the immuno-
assays are used to evaluate with a range of sam-
ples that challenge their analytical performance. 
Laboratory professionals should be aware of these 
issues when changing methods in their routine 
work and comparing results obtained from differ-
ent platforms. 
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